-
公开(公告)号:EP2821402A4
公开(公告)日:2015-08-19
申请号:EP13754501
申请日:2013-02-26
发明人: KAMEDA MINORU , KURIWAKI IKUMI , IIKUBO KAZUHIKO , HISAMICHI HIROYUKI , KAWAMOTO YUICHIRO , MORITOMO HIROYUKI , SUZUKI TOMOYUKI , FUTAMI TAKASHI , SUZUKI ATSUSHI , TSUNOYAMA KAZUHISA , ASAUMI MAKOTO , TOMIYAMA HIROSHI , NODA ATSUSHI , IWAI YOSHINORI , TOKUZAKI KAZUO , OKADA HARUKI , MIYASAKA KOZO
IPC分类号: C07D239/42 , A61K31/4545 , A61K31/506 , A61P35/00 , A61P43/00 , C07D239/47 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D413/12 , C07D471/10 , C07D487/20
CPC分类号: C07D239/47 , C07D239/42 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07D451/02 , C07D451/04 , C07D453/02 , C07D471/08 , C07D471/10 , C07D487/10 , C07D491/107
摘要: Provided is a compound useful as a prophylactic and/or therapeutic agent for bladder cancer. As a result of studies on compounds having FGFR inhibitory action, the present inventors have found that the nitrogen-containing aromatic heterocyclic compounds of the present invention have inhibitory action on FGFR1, FGFR2, and/or FGFR3, particularly, mutant FGFR3, and thus, the present invention has been accomplished. The nitrogen-containing aromatic heterocyclic compound of the present invention can be used as a therapeutic agent for various cancers related to FGFR1, FGFR2, and/or FGFR3, such as lung cancer and hormone therapy-resistant breast cancer, stomach cancer, triple negative breast cancer, endometrial cancer, bladder cancer, and glioblastoma, particularly as a prophylactic and/or therapeutic agent for mutant FGFR3-positive bladder cancer.
-
公开(公告)号:EP2565190A4
公开(公告)日:2013-08-21
申请号:EP11775050
申请日:2011-04-27
申请人: ASTELLAS PHARMA INC
发明人: HACHIYA SHUNICHIRO , MIURA MASANORI , IMAMURA YOSHIMASA , KAGA DAISUKE , SATO IPPEI , MORITOMO HIROYUKI , KATO KOJI , TERAI KAZUHIRO , TERADA YOH
IPC分类号: C07D333/68 , A61K31/381 , A61K31/4025 , A61K31/4436 , A61K31/4535 , A61K31/496 , A61K31/5377 , A61K31/55 , A61P3/12 , A61P9/00 , A61P13/12 , A61P43/00 , C07D409/12
CPC分类号: C07D333/66 , A61K31/381 , A61K31/4025 , A61K31/4436 , A61K31/444 , A61K31/4535 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K31/55 , A61K31/63 , A61K31/7042 , C07D333/68 , C07D409/12
-
公开(公告)号:EP1806347A4
公开(公告)日:2009-07-01
申请号:EP05790537
申请日:2005-10-05
申请人: ASTELLAS PHARMA INC
发明人: YONETOKU YASUHIRO , NEGORO KENJI , ONDA KENICHI , HAYAKAWA MASAHIKO , SASUGA DAISUKE , NIGAWARA TAKAHIRO , IIKUBO KAZUHIKO , MORITOMO HIROYUKI , YOSHIDA SHIGERU , OHISHI TAKAHIDE
IPC分类号: C07D471/04 , A61K31/519 , A61K31/5377 , A61K31/54 , A61K31/55 , A61P3/10 , A61P5/50 , A61P43/00 , C07D495/04 , C07D513/04
CPC分类号: C07D471/04 , C07D495/04 , C07D513/04
摘要: A novel pyrimidine derivative in which pyrimidine has been fused with an aromatic heterocycle selected among thiophene, thiazole, and pyridine or a pharmaceutically acceptable salt of the derivative; and a medicinal composition containing the compound or salt as an active ingredient. These compounds have excellent activity in accelerating insulin secretion and excellent activity in inhibiting the increase of a blood sugar level. Therefore, the medicinal composition containing the compound or salt as an active ingredient is useful, based on these activities, for the treatment and/or prevention of insulin-dependent diabetes mellitus (type 1 diabetes), noninsulin-dependent diabetes mellitus (type 2 diabetes), insulin-resistant diseases, and obesity.
-
公开(公告)号:EP2772484A4
公开(公告)日:2015-03-25
申请号:EP12840990
申请日:2012-10-17
申请人: ASTELLAS PHARMA INC
发明人: KAWAKAMI SHIMPEI , SAKURAI MINORU , KAWANO NORIYUKI , SUZUKI TAKAYUKI , SHIRAISHI NOBUYUKI , HAMAGUCHI WATARU , SEKIOKA RYUICHI , MORITOMO HIROYUKI , MORITOMO AYAKO
IPC分类号: C07D231/56 , A61K31/416 , A61K31/4184 , A61K31/4192 , A61K31/4245 , A61K31/437 , A61K31/4439 , A61K31/4709 , A61K31/497 , A61K31/501 , A61K31/502 , A61K31/506 , A61K31/517 , A61K31/5377 , A61P3/04 , A61P3/06 , A61P3/10 , A61P19/10 , A61P25/04 , A61P25/18
CPC分类号: C07D237/28 , C07D231/56 , C07D239/80 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/14 , C07D471/04
-
公开(公告)号:EP2138482A4
公开(公告)日:2011-06-15
申请号:EP08740535
申请日:2008-04-17
申请人: ASTELLAS PHARMA INC
IPC分类号: C07D217/24 , A61K31/472 , A61K31/517 , A61K31/5513 , A61K31/662 , A61K31/695 , A61P7/02 , A61P9/10 , A61P29/00 , A61P35/04 , A61P37/06 , A61P43/00 , C07D239/96 , C07D243/14 , C07D401/06 , C07D403/12 , C07D405/04 , C07D405/06 , C07D413/06 , C07D417/06
CPC分类号: C07D217/24 , C07D239/96 , C07D243/14 , C07D401/06 , C07D403/12 , C07D405/04 , C07D405/06 , C07D413/06 , C07D417/06
-
公开(公告)号:EP1995240A4
公开(公告)日:2009-12-09
申请号:EP07738511
申请日:2007-03-14
申请人: ASTELLAS PHARMA INC
发明人: KOGA YUJI , OKUDA TAKAO , WATANUKI SUSUMU , KAMIKUBO TAKASHI , HIRAYAMA FUKUSHI , MORITOMO HIROYUKI , FUJIYASU JIRO , KAGEYAMA MICHIHITO , UEMURA TOSHIO , TAKASAKI JUN
IPC分类号: C07D215/22 , A61K31/47 , A61K31/4709 , A61K31/519 , A61K31/5377 , A61K31/662 , A61K31/683 , A61K31/695 , A61P7/02 , A61P9/00 , A61P9/04 , C07D215/38 , C07D237/28 , C07D401/04 , C07D401/06 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/06 , C07D413/12 , C07D417/06 , C07D417/12 , C07D471/04
CPC分类号: C07F7/1856 , C07D215/22 , C07D215/56 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/04 , C07D405/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/14 , C07D487/04 , C07D513/04 , C07F9/60
-
公开(公告)号:EP2987793A4
公开(公告)日:2016-09-07
申请号:EP14786115
申请日:2014-04-18
申请人: ASTELLAS PHARMA INC
IPC分类号: C07D413/12 , A61K31/423 , A61K31/428 , A61K31/498 , A61P25/14 , A61P25/16 , A61P25/28 , A61P25/36 , C07D403/12 , C07D417/12
CPC分类号: C07D413/12 , C07D417/12
-
公开(公告)号:EP2194044A4
公开(公告)日:2011-11-23
申请号:EP08834496
申请日:2008-09-25
申请人: ASTELLAS PHARMA INC
发明人: ONDA KENICHI , IMAMURA KENICHIRO , SATO FUMIE , MORITOMO HIROYUKI , URANO YASUHARU , SAWADA YUKI , ISHIBASHI NAOKI , NAKANISHI KEITA , YOKOYAMA KAZUHIRO , FURUKAWA SHIGETADA , MOMOSE KAZUHIRO
IPC分类号: C07D215/22 , A61K31/47 , A61K31/4709 , A61K31/496 , A61K31/506 , A61K31/5377 , A61P1/16 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/10 , A61P9/12 , A61P13/12 , A61P19/02 , A61P25/00 , A61P25/28 , A61P27/02 , A61P29/00 , A61P35/00 , A61P39/06 , A61P43/00
CPC分类号: C07D401/12 , C07D215/233 , C07D401/06 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D491/107
-
公开(公告)号:EP1803710A4
公开(公告)日:2009-08-26
申请号:EP05793361
申请日:2005-10-17
申请人: ASTELLAS PHARMA INC
发明人: YONETOKU YASUHIRO , NEGORO KENJI , ONDA KENICHI , HAYAKAWA MASAHIKO , SASUGA DAISUKE , NIGAWARA TAKAHIRO , IIKUBO KAZUHIKO , MORITOMO HIROYUKI , YOSHIDA SHIGERU , OHISHI TAKAHIDE
IPC分类号: C07D239/70 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/55 , A61K31/551 , A61P3/10 , C07D239/94 , C07D401/04 , C07D403/04 , C07D487/04 , C07D491/048 , C07D495/04
CPC分类号: C07D239/70 , C07D239/94 , C07D495/04
摘要: A novel pyrimidine derivative, or pharmaceutically acceptable salt thereof, fused with a nonaromatic ring selected from among dihydrothiophene, dihydrofuran, a cycloalkyl, etc.; and a pharmaceutical composition comprising any of the above compounds as an active ingredient. These compounds exhibit excellent insulin secretion accelerating action and hyperglycemic action. Therefore, pharmaceutical compositions comprising the above compounds as an active ingredient due to the action thereof are useful in the therapy and/or prevention of insulin-dependent diabetes mellitus (type 1 diabetes), insulin-independent diabetes mellitus (type 2 diabetes), insulin resistant diseases, obesity, etc.
-
-
-
-
-
-
-
-